Supplementary Figure 1.
Manhattan plots for loci found to be significant in comparison of all IBD patients vs controls at the GWAS stage and positively verified by Taqman genotyping.
Supplementary Materials and Methods

Allelotyping GWAS
A pooled-DNA sample-based GWAS was performed as described previously 1 . Genomic DNA was extracted from whole blood treated with EDTA using a QIAamp DNA Mini Kit. DNA concentrations were measured using a Quant-iT TM PicoGreen dsDNA Kit (Invitrogen, United Kingdom). DNA integrity was verified by 1% agarose gel analysis.
DNA samples that passed quality control tests were grouped at equimolar concentrations by patient age at diagnosis, sex, and IBD diagnosis in order to obtain pools consisting of 23-24 DNA samples. Pooled DNA samples were adjusted to a final concentration of 50 ng/ml in Tris-EDTA buffer (pH 8). A total of 25, 24, and 30 DNA pools were prepared for CD, UC, and control samples, respectively. DNA pools were assayed independently on Illumina Human
Omni2.5-Exome BeadChips by the external AROS Applied Biotechnology A/S (Aarhus, Denmark) service. The datasets used in this GWAS are available in the GEO database under GSE79094.
Statistical analysis
For each SNP on each microarray in the GWAS, the relative allele signal (RAS) was calculated as described previously 1 . The RAS was used as an approximation of the allele ratio.
Due to a lack of call-rate statistics for pooled samples, quality was assessed by visual inspection of the first two principal components. Principal component analysis (PCA) was performed for subsets of 250,000 probes due to memory constraints. Six control pools and three UC pools were Manhattan plotting was performed using the qqman R package 3 . All computations were performed in the R environment 4 .
Individual genotyping
To validate the findings of the GWAS and replicate the SNP typing study, individual patients and controls were genotyped using TaqMan SNP Genotyping Assays (Life Technologies, USA) with TaqMan Universal Master Mix II and a 7900HT Real-Time PCR system (Life Technologies, USA). Associations were examined by the Fisher-exact test implemented in R (version 3.1.1). The ORs and 95% confidence intervals (CIs) were estimated by normal approximation using the EpiTools R package 5 . Significance threshold was set at 6.67E-4 (0.05/75), because 88 assessed SNPs represented 75 LD blocks.
Exome sequencing
A human exome sequencing library was prepared using the Ion AmpliSeq™ Exome Kit (Thermo Fisher) according to the manufacturer's protocol. Briefly, 100 ng of genomic DNA was subjected to multiplex amplification with 2x Exome Primer Pool. Next, primers were digested and adapters ligated to the amplicons. The samples were then purified using Agencourt AMPure XP beads (Beckman Coulter) and stored at -20°C for further processing. The concentration of each library was determined using a Qubit fluorometer (Thermo Fisher) and DNA fragment length assessed using High Sensitivity DNA Analysis Kits on a Bioanalyzer 2100 (Agilent). We investigated rare (MAF < 2%) deleterious variants present as homozygotes only in children (i.e., present in neither affected adults nor healthy controls). This allele frequency is based on frequency of rare, deleterious variant rs2066847 associated with IBD in European population.
We took into special consideration variants present in histocompatibility complex (HLA) genes, variants in genes previously associated with monogenic IBD according to the list provided by Uhlig et al. 13 (50 genes), and variants in genes previously associated with IBD according to the list provided by Jostins et al. 14 (1715 genes).
Over-representation of deleterious alleles among rare alleles
Only variants in coding regions with a global minor allele frequency (GMAF) featured in the 
